LSD tartrate

Phase 2Small molecule

RRadboud University Medical Center

LSD tartrate is one of 10 small molecule programs targeting Cluster headache. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cluster HeadacheRecruiting

Cluster HeadachePhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Cluster Headache

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Topamax

WWim Janssens

Approved

1 3

Botox

RRevance Therapeutics, Inc.

Phase 3

3 4

Zavzpret

Pfizer

Phase 2

1 5

Depakote

Low Sodium Oxybate

1 7

LSD tartrate

RRadboud University Medical Center

Phase 2

1 8

Levcromakalim

DDanish Headache Center

Preclinical

1 9

Acetium

BBiohit Oyj

Preclinical

1 10

Calcitonin Gene-Related Peptide

DDanish Headache Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Cluster Headache

NCT05477459

Clinical

Trials by Indication[1]

Cluster headache1 trial

LSD to Improve Cluster Headache Impact Trial

Recruiting·RRadboud University Medical Center·Phase 2·NCT05477459·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LSD tartrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LSD tartrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LSD tartrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radboud University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRadboud University Medical Center

LSD tartrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Cluster headache1 trial

References

Drug Info

Quick Facts

Related News